AUDREY ALBRACHT: Open Payments
NPI 1992412811 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$527 in 22 payments from 12 companies in 2025. Trend: 2023 $472 · 2024 $382 · 2025 $527
Food & beverage: $527
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $111 |
| Janssen Biotech, Inc. | 3 | $61 |
| Novartis Pharmaceuticals Corporation | 2 | $59 |
| SOBI, INC | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| AXOGEN | 1 | $36 |
| Merck Sharp & Dohme LLC | 2 | $29 |
| Novocure Inc. | 1 | $27 |
| JAZZ PHARMACEUTICALS INC. | 1 | $25 |
| Geron Corporation | 1 | $24 |
Products named: KISQALI, ENHERTU, LIBTAYO, RYBREVANT, Vonjo, IMFINZI, Optune Gio, ZEPZELCA.
Industry payments across TX — which companies pay providers there.
